ANEB

Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous treatment. Selonabant has completed dosing in a Phase II clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication. It is also prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with unintentional cannabis poisoning.